A USA-based foundation that was established in 1998 is currently funding new investment opportunities in the life science space (specifically Alzheimer’s disease and related dementia) through two grants; the first program is for existing early stage private companies, and the second program supports the establishment of new companies. The foundation typically provides funding of up to $350,000 per year for up to two years for pre-clinical programs or $1-3 M for clinical stage programs. The foundation will invest with other groups for larger deals. The foundation typically provides investments as equity, a convertible loan, and recoverable grants, and will consider investments globally.

The foundation is currently most interested in companies in the therapeutics space but will consider diagnostics, if the technology provides significant benefit for Alzheimer’s patients or will accelerate clinical trials. The firm is interested in both small molecules and biologics and will providing funding from companies anywhere from high throughput screening to Phase IIa of Clinical Trials.

The foundation is looking for companies with experienced management teams. The foundation looks to be an active value-added investor to help companies with securing future financing rounds when appropriate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A micro VC fund was founded in 2017 in the USA by a group of alumni from an established China-based university. The group has raised three funds in the past and is currently investing from the firm’s first fund of of $50 million since early 2017. The group focuses on Angel to Series A stage companies across various sectors, including pharmaceutical, medical device and healthcare IT. The typical investment size is no more than $500,000, but the group will syndicate with other investors for larger investments. The firm looks to make investments in US companies with markets in US and/or China.

The firm is currently looking for new opportunities in the life science space. The fund is opportunistic in terms of sectors, subsectors and indications. The fund typically invests in seed round and series A round. Historically, the fund has been active in life science companies developing synthetic organelles-based research tools, nanoparticle research reagents and devices, web-based EMR system, proprietary screening and diagnostic tests for cancer, drug authentication platform and patient recovery technologies.

The firm focuses on investments in private companies and typically invests in pre-revenue companies with strong and experienced management team. The firm will take a board seat or observer seat occasionally, depending on the investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An institutional alternative investor with several offices in Canada currently manages two venture funds: one fund is $100M in size and was raised in 2016, and the other fund is $300M in size and was raised in 2014. The firm prefers investing in companies that are on the market, but is willing to look at companies that are late into development and about to emerge onto the market.

The firm is agnostic towards their investments into the life sciences field for all their funds. With the first fund, the firm is looking to invest in companies in the British Columbia area which the firm believes can help grow the area. This first fund invests across four major technology sectors: Life sciences, CleanTech, Digital media and Information/Communications Technology. For the firm’s other larger venture fund, the firm is instead looking at more global markets and seeks to invest in companies that seem promising to them. Previous investments by the firm have been more involved in the technology sector.

The firm looks for experienced management teams. For the first fund, the firm cannot lead an investment, but prefers a board seat when investing. For the other fund, the firm is more flexible with leading, but still prefers a board seat when investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An active angel group based in Canada with more than 260 members considers early stage companies in a wide range of industry sectors including life sciences. The group can either lead or co-invest in a financing round in an average investment of $750K per deal. The group can make 30 investments per year. The group is seeking new opportunities across Canada and the USA.

Within life sciences, the group is most interested in early stage therapeutics, medical device, diagnostic, and healthcare IT innovations. The firm is open to all kinds of sectors and indications. In terms of therapeutics, the group will look at products of stages from pre-clinical to phase II.

The group is looking for competent entrepreneurs with sector expertise. The firm may take a board seat in applicable cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in California invests in a wide range of data-driven products that integrate AI, machine learning, and IoT. The firm is backed by a management team with a long, successful track record of building tech companies. The firm invests in the company’s early stages with an initial check size of $250 K with follow-on investments as the company matures, with equity and convertible loan as the preferred capital structures. The firm focuses on US-based companies, but may consider international companies with strongly innovative products that they can bring to the US market.

The firm will look at a range of verticals in the life sciences sector as long as there is a strong data-driven component in the company’s product. Sectors of interest include healthcare IT/digital health. The firm will not consider therapeutics or medical devices unless there is a heavy data component. The firm’s previous investments include an AI-driven image analysis platform for cancer detection, a computational DNA analysis platform for personalized cancer treatments, and a DNA amplification technology based on electric field-induced pH changes. The firm has their own AI Lab of top data scientists, so the company does not have to have the AI experts as long as they have the data, know how to get the data, and what information would be valuable to retrieve via machine learning applications.

The firm will work with companies backed by founders with deep domain expertise. The firm prefers deploying the venture studio model to help co-found companies, deploy their AI Lab experts, and will always take a board seat in their portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture capital arm of a global generic manufacturer is headquartered in the UK. The firm can invest $200K-$5m to a round. The firm will participate in rounds for digital health companies at all stages, as early as seed and through later venture rounds. The firm is open to working with companies globally.

Within digital health, the firm is seeking companies that are in the prevention and adherence space as well as digital medical devices and big data analytics platforms that address chronic diseases (Diabetes, Obesity and Cardiovascular), respiratory diseases, oncology, consumer and mental health. Past investments in the space include a wearable nicotine delivery device with integrated software and data analytics component to aid in smoking cessation.

The firm prefers to work with management teams with a track record in the space and a strong business plan.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.